Synklino
Carit has 20 years of pharmaceutical and biotech experience as a financial leader with several CFO positions. Carit is experienced in taking companies public on the Nordic stock exchanges and managing listed companies.
Synklino
1 followers
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.